Rapid, Accurate Prediction of TKI Treatment Response in Advanced EGFR-Mutant NSCLC Using the CODRP Platform

Patient-derived organoids (PDOs) have shown promise in modeling cancer therapy response, but their application in clinical decision-making is difficult. Results of a study that sought to address this challenge by developing a disposable nozzle-type cell spotter for efficient high-throughput screening (HTS) of cells from malignant pleural effusion were presented at the ESMO Targeted Anticancer Therapies Congress 2024.

The researchers collected cells from 14 patients with lung cancer. They used the HTS cell spotter for analysis along with the cancer organoid-based diagnosis reactivity prediction (CODRP) index, considering cancer cell proliferation rate and area under the curve (AUC) values, to evaluate epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drug sensitivity. Results were then compared with those obtained using the conventional AUC index.

Study findings showed the conventional AUC index did not effectively differentiate patients into sensitive and resistant groups for EGFR-TKI treatment. However, the CODRP index-based drug sensitivity test consistently correlated with the clinical drug treatment response, demonstrating the reliability of the CODRP index in predicting EGFR-TKI efficacy within a clinically suitable timeline of 14 days.

The researchers concluded that “PDO-based HTS combined with the CODRP index offers a promising approach to predict and analyze the effectiveness of anticancer drugs for lung cancer patients. By incorporating multiple parameters and utilizing patient-derived models, this strategy contributes to the development of a precision medicine platform. The CODRP index-based drug sensitivity test provides a reliable and timely tool for guiding treatment decisions, enabling personalized oncology care for lung cancer patients.”

Source: Park CK, et al. Rapid and accurate prediction of TKI treatment response in advanced EGFR-mutant non-small cell lung cancer using the CODRP platform. Abstract 56P. Presented at the ESMO Targeted Anticancer Therapies Congress 2024; February 26-28, 2024; Paris, France.